specific role of ephrins in bone biology. For example, how is expression of ephrinB2 and EphB4 regulated? Is their expression regulated by systemic factors or local factors that modulate bone remodeling? What is their relationship to common signaling pathways and other important genes involved in osteoclast and osteoblast differentiation? What is their relationship to the other molecular mechanisms proposed for coupling, including growth factors, and are these mechanisms mutually exclusive? Is this a common pathway utilized by all regulators of bone remodeling? Do cancer cells use similar bidirectional mechanisms to survive, proliferate, and/or use these mechanisms to cause the aberrations in osteoclast/osteoblast coupling that are characteristic of osteolytic and osteoblastic bone metastasis? The results of this provocative study have certainly provided the foundation for many new studies in this complex field.
Integrins are heterodimeric cell surface receptors used by cells to interact with the extracellular matrix (ECM). In addition to performing a structural role, integrins are major sites of signal initiation and modulation. In particular, integrins and receptor tyrosine kinases (RTKs) form a cooperative signaling network to regulate various biological processes (Hynes, 2002; Miranti and Brugge, 2002) . For instance, integrin adhesion promotes activation of several RTKs, including the epidermal growth factor receptor (EGFR). Conversely, RTKs affect cell adhesion, spreading, and migration by regulating integrin localization and activation. Cooperative signaling between RTKs and integrins may also have a role in cancer. Even though aberrant activation of RTKs and changes in integrin expression are involved in epithelial malignancies (carcinoma), it remains unclear how cooperation between integrins and RTKs regulates the initiation of tumor formation and progression to carcinoma.
In this issue of Cell, Guo et al. (2006) establish that α6β4 integrin, which binds to laminin in the ECM, is required for mammary tumorigenesis induced by expression of ErbB2, a member of the EGFR family of RTKs. ErbB2 is a dominant oncogene in breast cancer, and it is amplified in 25%-30% of human breast cancers. Amplification of ErbB2 correlates with poor clinical prognosis in patients whose cancer has progressed to the lymph nodes. ErbB2 is also the target of the drug Herceptin (Citri and Yarden, 2006 Integrins modulate signaling by growth factor receptors, but their role during tumorigenesis is not clear. Guo et al. (2006) now demonstrate that α6β4 integrin cooperates with ErbB2 in the formation of mammary tumors and discover distinct pathways that regulate cellular proliferation and adhesion downstream of the ErbB2-integrin complex.
signaling domain in the cytoplasmic portion of the β4 integrin subunit and another that expresses a mutant version of Neu (the rat homolog of human ErbB2). In the absence of β4 integrin's signaling domain, initiation and metastatic progression of mammary tumors that are induced by ErbB2 are significantly delayed, suggesting that α6β4 integrin acts as a cooperating oncogene. This notion is consistent with previous studies using other mouse model systems.
For instance, in a model of human epidermal neoplasia induced by Ras-NF-κB, primary human keratinocytes from patients with mutations in β4 integrin fail to form tumors when transplanted into nude mice (Dajee et al., 2003) . Also, α6β4 integrin cooperates with chemical carcinogens to induce invasive carcinoma when overexpressed in the suprabasal layer of mouse epidermis (Owens et al., 2003) . In addition to studies using α6β4, β1 integrin is required for initiation and progression of mouse mammary tumors induced by polyoma virus middle T antigen (White et al., 2004) . Thus, integrins can cooperate with diverse oncogenic signals.
The study reported by Guo et al. provides critical insight into the mechanism by which integrins cooperate with RTKs to cause transformation. ErbB2 and β4 integrin synergistically activate each other by coopting the cytoplasmic tyrosine kinase c-Src (Figure 1 ). ErbB2 induces Src-mediated phosphorylation of the signaling domain of β4 integrin by promoting formation of a multimeric complex, ErbB2-Src-α6β4 integrin. Src in turn phosphorylates ErbB2 in the P loop of the kinase domain, which enhances the kinase activity of ErbB2. These observations are consistent with previous studies that demonstrated a role for Src in the activation of EGFR that is induced by β1 integrin (Miranti and Brugge, 2002) . The importance of the β1 integrin-EGFR interaction in mammary epithelia was revealed by another study using three-dimensional (3D) culture models of cancer (Wang et al., 1998) . In a tumorigenic human mammary epithelial cell line that expresses high levels of EGFR and β1 integrin, downregulation of either β1 integrin or inhibition of EGFR results in downregulation of both β1 integrin and EGFR. This downregulation results in a reversion of the transformed phenotype, suggesting that the integrin-RTK interaction is required for maintaining a transformed state and that integrins may function to amplify oncogenic signaling from RTKs. Although several studies have demonstrated that integrin expression is misregulated in human cancers, the prognostic significance of integrin expression is not well understood. A comprehensive analysis of changes in coexpression of specific integrins and RTKs during human cancer progression may be of significant prognostic value.
Initiation and progression of epithelial malignancies in vivo are characterized not only by changes in proliferation rates but also by changes in epithelial organization and cell architecture. Changes in cell-cell and cell-matrix adhesions are the primary regulators of epithelial organization in vivo. Oncogenes, such as ErbB2, are known to disrupt epithelial organization by promoting cell proliferation and disruption of tight junctions, a cell-cell junctional complex located at the apex of polarized epithelial cells (Muthuswamy et al., 2001) . The study by Guo and colleagues sheds light on how oncogenes regulate epithelial architecture and proliferation. The cooperative signaling by ErbB2 and α6β4 integrins results in activation of two downstream pathways, c-Jun and STAT3, which are transcription factors that regulate oncogenesis. The authors demonstrate that activation of the c-Jun pathway is required for the changes in proliferation that are induced by ErbB2, whereas activation of STAT3 is required for ErbB2-induced disruption of tight junctions. A recent study also reported identification of distinct pathways that control cell polarity and proliferation using a 3D cell culture model. Inhibition of the PI3K pathway was sufficient to revert a malignant phenotype in human breast epithelial cells. Among the effectors of the PI3K signaling, Akt was required for cell proliferation, whereas the GTP binding protein Rac1 was required for changes in basal polarity of epithelial cells (Liu et al., 2004) . Interestingly, Rac1 can interact with STAT3, and EGF-induced activation of STAT3 requires Rac1 (Simon et al., 2000) . Together, these results raise the possibility that deregulation of cell architecture and cell proliferation may be under distinct regulatory control during the initiation and progression of carcinoma (Figure 1) . ErbB2 induces transformation of the polarized mammary epithelia by signaling through both α6β4 integrin-independent and -dependent pathways. ErbB2 regulates phosphorylation of the signaling domain of β4 integrin by promoting formation of a multimeric complex that includes ErbB2, the tyrosine kinase Src, and α6β4 integrin (Guo et al., 2006) . Src phosphorylates ErbB2 in the P loop of the kinase domain, which enhances the kinase activity of ErbB2. Cooperative signaling by ErbB2 and α6β4 integrins results in activation of c-Jun (via c-Jun N-terminal kinase, JNK) and STAT3, transcription factors that regulate oncogenesis. Activation of the c-Jun pathway is required for the changes in proliferation induced by ErbB2, whereas activation of STAT3 is required for ErbB2-induced disruption of tight junctions. In addition to α6β4-dependent pathways, ErbB2 may use the Ras/MAPK pathway to stimulate proliferation. It is not known whether ErbB2 uses α6β4 integrin-independent pathways to disrupt tight junctions and epithelial organization.
It is highly likely that there are integrin-dependent and -independent mechanisms that control transformation induced by oncogenes. Inhibition of signaling by β4 integrin significantly delayed the mammary tumorigenesis induced by ErbB2, but did not block it. Although the activation of Ras/MAPK mediated by ErbB2 could account for the proliferation observed in tumors formed in the absence of the β4 integrin signaling domain, it is not known whether there are β4-independent mechanisms that mediate ErbB2-induced disruption of tight junctions and epithelial organization. Further investigations are needed to answer questions such as: what are the pathways used by oncogenes to disrupt cell polarity? Are these pathways selective for deregulation of cell architecture (Figure 1) 
